Icon of the Instituts for Quality and Efficiency in Health Care

[A25-148] Pembrolizumab (head and neck squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V

Last updated 24.02.2026

Project no.:
A25-148

Commission:
Commission awarded on 24.11.2024 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission work started

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

First-line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma

Result of dossier assessment:

Added benefit not proven

DOI:

https://doi.org/10.60584/A25-53_en

Project no. Title Status
A15-33 Pembrolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment) Commission completed
A16-55 Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A17-06 Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A17-23 Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A17-46 Pembrolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A18-67 Pembrolizumab (head and neck squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A18-89 Pembrolizumab (urothelial carcinoma, first line) - Benefit assessment according to §35a Social Code Book V (new scientific findings) Commission completed
A19-29 Pembrolizumab (melanoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A19-30 Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A19-31 Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A19-99 Pembrolizumab (combination with axitinib, renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A19-100 Pembrolizumab (head and neck squamous cell carcinoma, monotherapy) - Benefit assessment according to §35a Social Code Book V Commission completed
A19-101 Pembrolizumab (head and neck squamous cell carcinoma, combination therapy) - Benefit assessment according to §35a Social Code Book V Commission completed
A21-34 Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Commission completed
A21-35 Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A21-36 Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A21-144 Pembrolizumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A21-145 Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V Commission completed
A21-163 Pembrolizumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A21-164 Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V Commission completed
A22-63 Pembrolizumab (breast cancer) - Benefit assessment according to § 35a Social Code Book V Commission completed
A22-70 Pembrolizumab (cervical cancer) – Benefit assessment according to § 35a SGB V Commission completed
A22-71 Pembrolizumab (renal cell carcinoma) – Benefit assessment according to § 35a SGB V Commission completed
A22-72 Pembrolizumab (melanoma, adjuvant) – Benefit assessment according to § 35a SGB V Commission completed
A22-73 Pembrolizumab (melanoma, advanced) – Benefit assessment according to § 35a SGB V Commission completed
A22-75 Pembrolizumab (colorectal cancer) – Benefit assessment according to § 35a SGB V Commission completed
A22-76 Pembrolizumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A22-77 Pembrolizumab (gastric cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A22-78 Pembrolizumab (small bowel cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A22-79 Pembrolizumab (bile cancer) – Benefit assessment according to § 35a SGB V Commission completed
A24-01 Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) – Benefit assessment according to §35a Social Code Book V Commission completed
A24-02 Pembrolizumab (gastric cancer, HER2-negative) – Benefit assessment according to §35a Social Code Book V Commission completed
A24-03 Pembrolizumab (biliary cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A24-46 Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V Commission completed
A24-47 Pembrolizumab (NSCLC, adjuvant) – Benefit assessment according to § 35a Social Code Book V Commission completed
A24-99 Pembrolizumab (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V Commission completed
A24-104 Pembrolizumab (TNBC, neoadjuvant and adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision) Commission completed
A24-110 Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – Benefit assessment according to §35a Social Code Book V Commission completed
A24-111 Pembrolizumab (endometrial carcinoma) – Benefit assessment according to §35a Social Code Book V Commission completed
A25-53 Pembrolizumab (pleural mesothelioma) – Benefit assessment according to §35a Social Code Book V Commission completed

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page